Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 11/20 | 1.00 |
| ▸ | SRD5A2 | P31213 | 9/20 | 1.00 |
| ▸ | FNTA | P49354 | 1/20 | 0.56 |
| ▸ | FNTB | P49356 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17817402 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2FNTAFNTBCYP2D6 | |
| SCHEMBL8965032 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2FNTAFNTBCYP2D6 | |
| SCHEMBL4448193 | 0.91 | SRD5A1 (0.83) | SRD5A1SRD5A2 | |
| SCHEMBL4635878 | 0.86 | SRD5A2 (0.76) | SRD5A1SRD5A2FNTAFNTB | |
| SCHEMBL8347913 | 0.86 | SRD5A1 (0.76) | SRD5A1SRD5A2 | |
| SCHEMBL8063981 | 0.86 | SRD5A2 (0.75) | SRD5A1SRD5A2 | |
| SCHEMBL8063986 | 0.86 | SRD5A2 (0.75) | SRD5A1SRD5A2 | |
| SCHEMBL8577505 | 0.85 | SRD5A2 (1.00) | SRD5A1SRD5A2FNTAFNTB | |
| SCHEMBL1290263 | 0.85 | SRD5A1 (0.73) | SRD5A1SRD5A2FNTAFNTBCYP2D6 | |
| SCHEMBL8578390 | 0.85 | SRD5A2 (1.00) | SRD5A1SRD5A2FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5543417-A | 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent | MERCK & CO., INC. (US) | 1996-08-06 | — | — | US | disclosed |
| US-5527807-A | TREATING ALOPECIA, ACNE, PROSTATE DISORDERS | MERCK & CO., INC. (US) | 1996-06-18 | — | — | US | disclosed |
| WO-1996012487-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | disclosed |
| WO-1996012817-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | disclosed |
| WO-1995013077-A1 | 7β-SUBSTITUTED-4-AZA-5α-CHOLESTAN-3-ONES AS SELECTIVE 5α-REDUCTASE 1 INHIBITORS | MERCK & CO., INC. (US) | 1995-05-18 | — | — | WO | disclosed |
| EP-0572165-A1 | New 7B-substituted-4-aza-5a-cholestan-ones as 5a-reductase inhibitors | MERCK & CO. INC. (US) | 1993-12-01 | — | — | EP | disclosed |
| WO-1993023419-A1 | NEW 7β-SUBSTITUTED-4-AZA-5α-CHOLESTAN-ONES AS 5α-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | disclosed |